---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-273317"
form_type: "8-K"
ticker: "QDEL"
cik: "0001906324"
company_name: "QuidelOrtho Corp"
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:40:49.985637+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# QuidelOrtho Q3: revenue $700M, adj. EBITDA margin 25%, core growth 5% YoY

## Summary
- Total revenue $700M; core revenue (ex-COVID/Donor Screening) grew 5% as reported.
- Adjusted EBITDA margin improved 180 bps to 25%; full-year guidance maintained at 22%.
- Labs +4%, IH +5%, Triage +7% (constant currency); non-respiratory up 6% CC.
- Respiratory revenue $112M (-32% YoY); COVID sales down 63%.
- Pending LEX Diagnostics acquisition on track; VITROS High Sensitivity Troponin cleared in U.S.

## SEC filing metadata
- accession: 0001193125-25-273317
- form_type: 8-K
- ticker: QDEL
- cik: 0001906324
- company_name: QuidelOrtho Corp
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1906324/000119312525273317/0001193125-25-273317-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1906324/000119312525273317/d79385d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-273317
- JSON: https://secwatch.observer/filing/0001193125-25-273317.json
- Plain text: https://secwatch.observer/filing/0001193125-25-273317.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.